Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491607 | ||
| 003 | CHVBK | ||
| 005 | 20210128100510.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0810-y |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0810-y | ||
| 245 | 0 | 0 | |a Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial |h [Elektronische Daten] |c [Yasuo Hirayama, Kunihiko Ishitani, Yasushi Sato, Satoshi Iyama, Kohichi Takada, Kazuyuki Murase, Hiroyuki Kuroda, Yasuhiro Nagamachi, Yuichi Konuma, Akihito Fujimi, Tamotsu Sagawa, Kaoru Ono, Hiroto Horiguchi, Takeshi Terui, Kazuhiko Koike, Toshiro Kusakabe, Tsutomu Sato, Rishu Takimoto, Masayoshi Kobune, Junji Kato] |
| 520 | 3 | |a Background: Chemotherapy-induced peripheral neuropathy (CIPN) is difficult to manage. A phase III trial conducted in the United States demonstrated that duloxetine was effective for CIPN caused by taxane and platinum-based chemotherapy. No randomized trial of duloxetine for CIPN has been conducted in Japan. Methods: In this open-label, randomized, crossover study, eligible patients were randomized to Group A or Group B. Group A received duloxetine 20mg/day orally for the first week and 40mg/day for the next 3weeks. Group B received vitamin B12 (VB12) 1.5mg/day orally for 4weeks. After a 2- to 4-week washout period, treatment was crossed over for another 4weeks. The severity of numbness and pain was assessed using a visual analog scale (VAS). Results: Thirty-four patients were enrolled. Obvious decreases in the mean VAS scores for numbness and pain were observed for the periods of duloxetine administration. Significant differences were observed between the duloxetine-first (Group A) and the VB12-first (Group B) groups with respect to numbness (p=0.03) and pain (p=0.04) at 4weeks after administration. Fatigue was observed in six of the 34 participants (17.6%). Conclusions: Our data suggests that duloxetine has a beneficial effect on CIPN caused by oxaliplatin, paclitaxel, vincristine, or bortezomib in Japanese patients. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a Duloxetine |2 nationallicence | |
| 690 | 7 | |a Neuropathy |2 nationallicence | |
| 690 | 7 | |a Chemotherapy |2 nationallicence | |
| 690 | 7 | |a Supportive care |2 nationallicence | |
| 690 | 7 | |a CIPN |2 nationallicence | |
| 700 | 1 | |a Hirayama |D Yasuo |u Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Ishitani |D Kunihiko |u Division of Palliative Care, Higashi Sapporo Hospital, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Sato |D Yasushi |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Iyama |D Satoshi |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Takada |D Kohichi |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Murase |D Kazuyuki |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Kuroda |D Hiroyuki |u Department of Hematology Oncology, Seitetsu Memorial Hospital, Muroran, Japan |4 aut | |
| 700 | 1 | |a Nagamachi |D Yasuhiro |u Department of Hematology Oncology, Kiyota Hospital, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Konuma |D Yuichi |u Department of Hematology Oncology, Asahikawa Red Cross Hospital, Asahikawa, Japan |4 aut | |
| 700 | 1 | |a Fujimi |D Akihito |u Department of Hematology Oncology, Oji Genaral Hospital, Tomakomai, Japan |4 aut | |
| 700 | 1 | |a Sagawa |D Tamotsu |u Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Ono |D Kaoru |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Horiguchi |D Hiroto |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Terui |D Takeshi |u Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Koike |D Kazuhiko |u Division of Palliative Care, Higashi Sapporo Hospital, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Kusakabe |D Toshiro |u Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Sato |D Tsutomu |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Takimoto |D Rishu |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Kobune |D Masayoshi |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 700 | 1 | |a Kato |D Junji |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/5(2015-10-01), 866-871 |x 1341-9625 |q 20:5<866 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0810-y |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0810-y |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hirayama |D Yasuo |u Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ishitani |D Kunihiko |u Division of Palliative Care, Higashi Sapporo Hospital, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sato |D Yasushi |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Iyama |D Satoshi |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takada |D Kohichi |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Murase |D Kazuyuki |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kuroda |D Hiroyuki |u Department of Hematology Oncology, Seitetsu Memorial Hospital, Muroran, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nagamachi |D Yasuhiro |u Department of Hematology Oncology, Kiyota Hospital, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Konuma |D Yuichi |u Department of Hematology Oncology, Asahikawa Red Cross Hospital, Asahikawa, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fujimi |D Akihito |u Department of Hematology Oncology, Oji Genaral Hospital, Tomakomai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sagawa |D Tamotsu |u Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ono |D Kaoru |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Horiguchi |D Hiroto |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Terui |D Takeshi |u Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Koike |D Kazuhiko |u Division of Palliative Care, Higashi Sapporo Hospital, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kusakabe |D Toshiro |u Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sato |D Tsutomu |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takimoto |D Rishu |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kobune |D Masayoshi |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kato |D Junji |u Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/5(2015-10-01), 866-871 |x 1341-9625 |q 20:5<866 |1 2015 |2 20 |o 10147 | ||